JP2012528185A - ｃ−Ｍｅｔタンパク質キナーゼの置換ピラゾール阻害剤 - Google Patents

ｃ−Ｍｅｔタンパク質キナーゼの置換ピラゾール阻害剤 Download PDF

Info

Publication number
JP2012528185A
JP2012528185A JP2012513239A JP2012513239A JP2012528185A JP 2012528185 A JP2012528185 A JP 2012528185A JP 2012513239 A JP2012513239 A JP 2012513239A JP 2012513239 A JP2012513239 A JP 2012513239A JP 2012528185 A JP2012528185 A JP 2012528185A
Authority
JP
Japan
Prior art keywords
compound
cancer
hydrogen
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012513239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528185A5 (enExample
Inventor
パン リ，
ネイサン ワール，
スティーブン ロンキン，
チン タン，
デイビッド ラウファー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2012528185A publication Critical patent/JP2012528185A/ja
Publication of JP2012528185A5 publication Critical patent/JP2012528185A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2012513239A 2009-05-28 2010-05-27 ｃ−Ｍｅｔタンパク質キナーゼの置換ピラゾール阻害剤 Pending JP2012528185A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18178409P 2009-05-28 2009-05-28
US61/181,784 2009-05-28
PCT/US2010/036309 WO2010138663A1 (en) 2009-05-28 2010-05-27 Substituted pyrazole inhibitors of c-met protein kinase

Publications (2)

Publication Number Publication Date
JP2012528185A true JP2012528185A (ja) 2012-11-12
JP2012528185A5 JP2012528185A5 (enExample) 2013-07-11

Family

ID=42370912

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012513239A Pending JP2012528185A (ja) 2009-05-28 2010-05-27 ｃ−Ｍｅｔタンパク質キナーゼの置換ピラゾール阻害剤

Country Status (8)

Country Link
US (3) US8269012B2 (enExample)
EP (1) EP2435444A1 (enExample)
JP (1) JP2012528185A (enExample)
CN (1) CN102448968A (enExample)
AU (1) AU2010254053A1 (enExample)
CA (1) CA2762186A1 (enExample)
MX (1) MX2011012522A (enExample)
WO (1) WO2010138663A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528186A (ja) * 2009-05-28 2012-11-12 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのアミノピラゾールトリアゾロチアジアゾール阻害剤
JP2019505581A (ja) * 2015-12-31 2019-02-28 ベイジン・パール・バイオテクノロジー・リミテッド・ライアビリティ・カンパニー 神経膠腫の治療用の薬剤の調製における化合物の使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2712717T3 (es) * 2012-07-27 2019-05-14 Sato Pharma Compuesto de difluorometileno
CN103073491A (zh) * 2013-01-25 2013-05-01 桑迪亚医药技术（上海）有限责任公司 一种2-（5,7-二氟-6-喹啉基）乙酸/丙酸（酯）的合成方法
GR1009565B (el) * 2016-07-14 2019-08-06 Galenica Α.Ε. Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
CN109897054B (zh) * 2017-12-08 2021-12-10 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144767A1 (en) * 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
JP2012509279A (ja) * 2008-11-19 2012-04-19 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
JP2012528186A (ja) * 2009-05-28 2012-11-12 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのアミノピラゾールトリアゾロチアジアゾール阻害剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000660A1 (fr) * 2001-06-22 2003-01-03 Kirin Beer Kabushiki Kaisha Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive
EP1713484A2 (en) * 2004-01-23 2006-10-25 Amgen Inc. Compounds and methods of use
ATE492544T1 (de) * 2004-08-26 2011-01-15 Pfizer Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
NZ568666A (en) * 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144767A1 (en) * 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
JP2012509279A (ja) * 2008-11-19 2012-04-19 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
JP2012528186A (ja) * 2009-05-28 2012-11-12 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのアミノピラゾールトリアゾロチアジアゾール阻害剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012528186A (ja) * 2009-05-28 2012-11-12 バーテックス ファーマシューティカルズ インコーポレイテッド ｃ−Ｍｅｔタンパク質キナーゼのアミノピラゾールトリアゾロチアジアゾール阻害剤
JP2019505581A (ja) * 2015-12-31 2019-02-28 ベイジン・パール・バイオテクノロジー・リミテッド・ライアビリティ・カンパニー 神経膠腫の治療用の薬剤の調製における化合物の使用

Also Published As

Publication number Publication date
EP2435444A1 (en) 2012-04-04
US20130018072A1 (en) 2013-01-17
US8269013B2 (en) 2012-09-18
US20110124684A1 (en) 2011-05-26
CA2762186A1 (en) 2010-12-02
CN102448968A (zh) 2012-05-09
MX2011012522A (es) 2012-02-08
US8269012B2 (en) 2012-09-18
AU2010254053A1 (en) 2011-12-01
WO2010138663A1 (en) 2010-12-02
US20100305155A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
JP5596047B2 (ja) ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
JP5686796B2 (ja) ｃ−Ｍｅｔタンパク質キナーゼのアミノピラゾールトリアゾロチアジアゾール阻害剤
US8269013B2 (en) Substituted pyrazole inhibitors of c-Met protein kinase
US8263776B2 (en) Inhibitors of c-Met protein kinase
HK1169401A (en) Substituted pyrazole inhibitors of c-met protein kinase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140627

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141119